Site en français

LUtetium-177 DOsimetry as a predictive biomarker of response in metastatic castrate-resistant prostate cancer patients treated with PSMA radioligand THerapy.

Units : Radiophysics and MRI physics laboratory | ULB836

Description :

177Lu-labelled prostate-specific membrane antigen (177Lu-PSMA) is a type of vectorised molecular radiotherapy that has shown
promising results in prospective trials for the treatment of metastatic castrate resistant prostate cancer patients progressing to
other systemic threrapies. An optimization of the therapeutic outcome by maximizing the dose delivered to the tumour, while keeping
the dose delivered to organs at an acceptable risk level (mainly bone marrow and salivary glands) is the main goal of dosimetry.
Systematically implemented patient-based dosimetry analysis is essential in order to fully exploit the therapeutic potential of
177Lu-PSMA. Furthermore, accurate and precise dosimetric estimations are crucial for establishing a correlation between absorbed dose
and treatment efficacy and safety. Our aim is to study the correlation between dosimetry and reponse/toxicity. Knowing these
relationships, will enable early detection of non-responders and/or patients with potential development of acute toxicities, adapting
patient care in an optimal timeline manner with the overarching objective of improving patients’ quality of life and outcome.

List of persons in charge :


List of lessors :

  • Financement de base institutionnel